Myeloproliferative Neoplasms News

  Healio spoke with Akriti Jain, MD, about aproaching the treatment of myelodysplastic syndrome based on where patients lie on the MDS spectrum.

Healio spoke with Akriti Jain, MD, about the pre-MDS conditions that have the potential to progress into MDS if left untreated.

Healio spoke with Akriti Jain, MD, about recent diagnostic and treatment developments in MDS.

Healio spoke with Akriti Jain, MD, about the future of MDS research, specifically combination treatments like azacitidine and venetoclax.

This year’s ASH Annual Meeting featured several high-impact abstracts.

In this video, Lindsay A.M. Rein, MD, discussed the Summit trial into treatment of systemic mastocytosis, data from which was presented at the ASH Annual Meeting and Exposition.

In this video, Lindsay A.M. Rein, MD, discussed the TRANSFORM-1 and MANIFEST-2 trials into combination therapies in myelofibrosis, both of which were presented at the ASH Annual Meeting and Exposition.

In this video, Lindsay A.M. Rein, MD, discussed the phase 1/phase 2 TP-3654 study into relapsed/refractory myelofibrosis, data from which she presented at the ASH Annual Meeting and Exposition.

SAN DIEGO — First-line treatment with ruxolitinib led to “clinically meaningful” positive results versus best available therapy in patients with high-risk polycythemia vera, according to data presented at ASH Annual Meeting.

SAN DIEGO — Patients with Philadelphia chromosome-negative accelerated- or blast-phase myeloproliferative neoplasms who received allogeneic hematopoietic stem cells had a longer median OS than those who did not, according to a study.